Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
LOXO-RAS-20001
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT04956640 ↗
- Active, not recruiting
- Eli Lilly and Company
- Deep
We haven't built an HCP commentary report on LOXO-RAS-20001 (olomorasib (LY3537982); olomorasib (LY3537982) plus pembrolizumab; olomorasib (LY3537982) plus cetuximab in KRAS G12C-mutant advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LOXO-RAS-20001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 54 | |
| YouTube | 1 | |
| Podcasts | 1 | |
| Bluesky threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms
- Interventions
- LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin
- Arms
- LY3537982 (Dose Escalation) · Experimental
- LY3537982 (Dose Expansion) · Experimental
- LY3537982 (Dose Optimization) · Experimental
- Enrollment
- 540 (estimated)
- Primary outcomes
- Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy
- Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents
- Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab
- To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab
- To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation
- Sponsor
- Eli Lilly and Company with Merck Sharp & Dohme LLC
- Start
- Jul 19, 2021
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04956640 · updated May 29, 2026